Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield
The article compares Johnson & Johnson (JNJ) and AbbVie (ABBV) on dividends and recent results. JNJ reported Q2 worldwide sales of $25.3B and highlights a 64-year dividend increase streak with a 2.02% yield. ABBV reported nearly $17B revenue, a 2.78% yield, Skyrizi up 24% to $5.5B, Humira down 36.1% to $706M, and a $10.9B Apogee Therapeutics acquisition that reduces 2026 EPS by $0.14.
How this was made
The 30-second read
Why it matters
For JNJ, the key takeaway is relative income safety supported by long dividend history and cited Q2 breadth. For ABBV, the key takeaway is deal-driven EPS dilution (2026 EPS -$0.14) and the market’s focus on post-Humira product durability and upcoming decision points.
Market read
Traders may use the piece to frame relative positioning: JNJ as the defensive income choice and ABBV as the higher-yield, higher-execution-risk story with explicit deal-related EPS impact.
What to watch
The article flags patent cliff risk (Skyrizi composition-of-matter to 2033) but does not quantify competitive intensity, reimbursement dynamics, or integration execution risk for Apogee, which could dominate outcomes.
Background
The article compares J&J’s dividend safety and diversified pipeline versus AbbVie’s higher yield, immunology concentration, and a newly announced $10.9B Apogee Therapeutics acquisition.
Ticker impact
Article contrasts J&J’s 64-year dividend streak and Q2 sales growth, highlighting diversification and dividend safety versus AbbVie.
Mildly positive for JNJ on income-safety framing, but likely limited without new guidance or a fresh catalyst.
The piece is primarily comparative and opinion-led, but it cites specific Q2 performance and product momentum that can support relative positioning.
Article reports AbbVie’s $10.9B Apogee Therapeutics acquisition and states it knocks $0.14 off 2026 EPS, alongside immunology concentration.
Potentially mixed, with downside risk from EPS hit offset by upside optionality if post-Humira products sustain.
The acquisition and explicit 2026 EPS impact are concrete, but the rest is largely thesis framing rather than incremental deal terms or updated guidance.
Market effects
Reinforces a healthcare income-versus-growth trade-off: diversified dividend payers vs immunology-heavy portfolios with M&A-driven EPS optics.
Primarily US large-cap healthcare positioning, with limited direct regional spillover.
Could influence global pharma relative-value flows between dividend defensives and immunology growth stories.
Counterpoint
ABBV’s higher yield may be less about risk and more about market underpricing of post-Humira durability; the EPS hit could be temporary if Apogee accelerates long-acting biologics adoption.
Key entities
- public_companyJohnson & Johnson
Dividend King with 64 consecutive years of raises; article cites Q2 sales growth and product momentum.
- public_companyAbbVie
Higher-yield pharma with immunology concentration; article cites Q2 immunology performance and a $10.9B Apogee acquisition impacting 2026 EPS.
- public_companyApogee Therapeutics
Acquired by AbbVie in a $10.9B deal described as adding long-acting biologics for atopic dermatitis and respiratory disease.
